See Clinical Research on Page 535
Nephrolithiasis is one of the most widespread urinary disorders, and calcium, as calcium-oxalate
or -phosphate, is by far the most frequent component of stones. Idiopathic nephrolithiasis
is generally acknowledged as a disorder caused by the interaction of multiple genetic
and environmental factors. Family studies showed a non-mendelian transmission of idiopathic
nephrolithiasis.
1
In addition, a small group of rare monogenic disorders (distal tubular acidosis, Dent
diseases, primary oxalosis) may develop calcium nephrolithiasis.
2
The overall contribution of genetic determinants to kidney stones in a population
may be estimated as heritability according to criteria of classic genetics.
3
Heritability of kidney stones may be computed by taking account of the concordance
rate for nephrolithiasis in monozygotic and dizygotic twin pairs.
3
This approach was used by Goldfarb et al.4 in their article published in the present
issue of Kidney International Reports. These authors already analyzed male monozygotic
and dizygotic twin pairs selected from the Vietnam Era Twin Registry in a previous
work published in 2005. In these male twins, concordance rate for nephrolithiasis
was found higher in monozygotic than dizygotic twins and heritability value was estimated
to be 56%.
5
In the present study, these authors selected twins from the Washington State Twin
Registry and for the first time calculated heritability in women and men separately.
Monozygotic twins showed again a higher concordance rate for stones in comparison
with dizygotic twins, and the value of heritability detected in men (57%) confirmed
that previously observed in twins from the Vietnam Era Twin Registry and in other
family studies,
1
whereas its value was significantly lower (46%) in women.4, 5 These findings indicate
that genetic determinants may be more relevant for stone susceptibility in men than
in women and this could contribute to explain the higher frequency of kidney stones
in men.
Mutations at 4 genes located in the X-chromosome may cause monogenic forms of nephrolithiasis
2
: OCRL (Xq26.1) and CLCN5 (Xp11.23) may cause calcium stones; PRPS (Xq22.3) and HGPRT
(Xq26.2-q26.3) may cause uric acid stones. The OCRL gene (OMIM 3000535) encodes a
phosphatidylinositol 4,5-bisphosphate-5-phosphatase located in the trans-Golgi network
that regulates actin polymerization and the formation of tight and adherens junctions
in the proximal tubule. Mutations at the OCRL gene cause oculocerebro-renal Lowe syndrome
and the less severe Dent disease type 2, a proximal tubule disorder with multiple
defects of reabsorption. CLCN5 (OMIM 300009) encodes a voltage-gated chloride ion
channel localized in the brush border and endocytosis vesicles in proximal tubular
cells; this channel provides an electrical shunt necessary for the acidification of
vesicle fluid and endocytosis pathway; its mutations cause Dent disease type 1, phenotypically
indistinguishable from the type 2 disease. PRPS (OMIM 311850) encodes phosphoribosyl
pyrophosphate synthase, which is necessary for a correct purine and pyrimidine biosynthesis;
superactivity of this enzyme results in an excessive purine production, hyperuricemia,
hyperuricosuria, gout, and uric acid stones. Finally, HGPRT (OMIM 308000) encodes
hypoxanthine-guanine phosphoribosyl-transferase; its mutations lead to hypoxanthine
and guanine accumulation and cause overproduction of uric acid, gout, and uric acid
nephrolithiasis; complete deficiency of this enzyme causes Lesch-Nyhan syndrome. Allele
variants in these 4 genes may increase susceptibility to idiopathic calcium and uric
acid nephrolithiasis in men, but it is likely that variants at other genes located
in the X-chromosome also may contribute to stone production.
2
Different models of genetic determination may underlie idiopathic nephrolithiasis:
variants in a few specific loci could be necessary to promote stone production and,
thus, exert a dominant effect; alternatively, multiple additive genes, each of them
unable to cause stones by themselves, may sum their effects to increase stone risk
and cause stone formation.
3
Each of these genetic models may be causal in distinct stone former groups, even though
dominant and additive genes may coexist and mutually influence stone risk in patients.
This complex background is further complicated by environmental factors that may influence
gene expression with their epigenetic effects. In addition, many variables predisposing
to kidney stones are multifactorial traits, like hypercalciuria, hypocitraturia, urinary
tract obstruction, and Randall plaque extent.
6
In the context of nephrolithiasis, findings of phenotype-genotype association studies,
either testing the whole genome or candidate genes, identified a group of loci associated
with kidney stones in different populations: CASR (3q13.3-q21.1), CLDN14 (21q22.13),
ALPL (1p36.12), TRPV5 (7q34), SLC34A1 (5q35.3), ORAI1 (12q24.31), KL (13q13.1), DGKH
(13q14.11), AQP1 (7p14.3), MGP (12p12.3), SPP1 (4q22.1), VDR (12q13.11), PLAU (10q22.2),
SLC26A1 (4p16.3), and SLC26A6 (3p21.3).
2
All these genes are autosomal and characteristics of their association with stones,
in terms of variant frequency and gene product activity, suggest that they could produce
additive effects in stone formation. A summary of tubular activities of their products
is shown in Figure 1.
2
Figure 1
Genes implicated in idiopathic kidney stones retrieved by replicated association studies.
2
The figure reports the activity of these gene products and their relative tubular
region of activity.
Recent works observed that idiopathic patients with early onset of stone disease may
carry variants in genes causing monogenic nephrolithiasis. These rare variants were
detected in 29% of patients with stone disease onset before 25 years
7
and were identified at the following loci: AGXT (2q37.3), ATP6V1B1 (2p13.3), CLDN16
(3q28), CLDN19 (1p34.2), GRHPR (9p13.2), SLC3A1 (2p21), SLC12A1 (15q21.1), SLC9A3R1
(17q25.1), SLC34A1 (5q35.3), VDR (12q13.11), ADCY10 (1q24.2), CYP24A1 (20q13.2), ATP6V0A4
(7q34), SLC7A9 (19q13.11), SLC2A9 (4p16.1), SLC22A12 (11q13.1), and SLC4A1 (17q21.31).
7, 8 Stone formers carrying these rare variants were characterized by nephrocalcinosis,
high rate of relatives with stones, and consanguineous parents, in addition to early
onset of the disease.
8
These characteristics suggest that these genes may significantly influence clinical
history of patients and stone risk, thus producing a dominant effect in stone disease.
Heritability estimates the averaged effect of genetic determinants on stone production
variance in a specific population.
3
The study of Goldfarb et al.
4
suggests that approximately one-half of susceptibility to kidney stones may be sustained
by genes; however, the weight of genes may be different and differently combined with
environmental factors in each stone former. Predicting stone risk in single individuals
needs to consider variants at all causal loci, environment characteristics, and epigenetic
effects of environmental factors on gene expression. Current technological advances
exploring genetic variants in the whole genome allow prediction of individual stone
risk and, together with improvements in statistical analysis methods, also estimation
of heritability of complex traits, like stone disease in unrelated individuals.
9
However, heritability estimated by such genomic tools cannot include epigenetic influences
and rare genetic variants, thus resulting in heritability estimates lower than those
provided by studies in twins. Only recovering such missing heritability in large cohorts
will provide a heritability estimation similar to that detected by twin studies.
9
In conclusion, heritability estimation by twin study remains a relevant reference
for modern genetic studies. The overall analysis of loci associated with nephrolithiasis
combined with findings of lifestyle analysis and epigenomic investigation may provide
stone-risk parameters useful for the clinical evaluation of patients by also taking
into account gender variability, as indicated by the present work of Goldfarb et al.
4
Disclosure
All the authors declared no competing interests.